ESMO 2017: Anti-programmed death 1 receptor drug pembrolizumab has significant antitumor activity in carcinoid and pancreatic neuroendocrine tumours


  • Oncology Conference Roundups
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In the KEYNOTE-028 trial, pembrolizumab, an anti-programmed death 1 receptor drug, provided meaningful antitumour activity in carcinoid and pancreatic neuroendocrine tumours.

Why this matters

  • Programmed death-ligand 1 expression is associated with a more aggressive disease.
  • Pembrolizumab provided an objective response rate of 12% in patients with carcinoid tumours and 6% in patients with pancreatic neuroendocrine tumour.
  • The response was durable (more than 6 months) and median time to response was lower than 2 months in both cohorts.

Study design

  • 276 patients with carcinoid tumours or well or moderately differentiated pancreatic neuroendocrine tumours and with previous failure of standard therapy were enrolled.
  • 36% were positive for programmed death-ligand 1.
  • Patients were treated with pembrolizumab for up to 2 years.
  • Treatment was interrupted in case of confirmed progression, intolerable toxicity or consent withdrawal.
  • The primary endpoint was objective response rate after the RECIST1.1 questionnaire (Response Evaluation Criteria In Solid Tumors).
  • Funding: Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London; Italian Ministry of Research, Italian Association for Cancer Research.

Key results

  • 3 patients with carcinoid tumour (12%) had a partial response, 15 (60%) were stable (32% for more than 6 months), and 7 (28%) had progressive disease.
  • 14 (88%) patients with pancreatic neuroendocrine tumours had stable disease (31% for more than 6 months), 1 (6%) showed a partial response, and 1 (6%) had progressive disease.
  • The only pancreatic neuroendocrine tumours responder has an ongoing response of 17.6 months.